Intellia Therapeutics Inc (OQ:NTLA)

Business Focus: Biotechnology & Medical Research

Sector:  Healthcare Industry:  Biotechnology & Medical Research
 
See Regulatory Filings on SEC
Company Contact
Address: 40 Erie St Ste 130
CAMBRIDGE MA 02139-4254
Tel: 1-857-7061612
Website: www.intelliatx.com
IR: See website
<
Key People
Frank A. G. M. Verwiel
Independent Chairman of the Board
John M. Leonard
President, Chief Executive Officer, Director
Glenn G. Goddard
Chief Financial Officer, Executive Vice President
Andrew D. Schiermeier
Chief Operating Officer, Executive Vice President
Laura Sepp-Lorenzino
Executive Vice President, Chief Scientific Officer
Jose E. Rivera
Executive Vice President, General Counsel
David Lebwohl
Executive Vice President, Chief Medical Officer
   
Business Overview
Intellia Therapeutics, Inc. is a genome editing company. The Company is focused on developing therapeutics utilizing a biological tool known as CRISPR/Cas9. The CRISPR/Cas9 genome editing system includes two components: the Cas9 protein and the guide RNA sequence. The Cas9 protein acts like a pair of molecular scissors that initiates the natural cellular repair process to knockout, repair or insert a gene. The guide RNA sequence recognizes and directs the Cas9 to a specific target deoxyribonucleic acid (DNA) sequence. The Company's sentinel in vivo programs focus on the use of Lipid Nanoparticle (LNPs) for delivery of the CRISPR/Cas9 complex to the liver. The Company's division, eXtellia Therapeutics, is focused on the application of CRISPR/Cas9 genome editing in the fields of immuno-oncology and autoimmune and inflammatory diseases. The Company's subsidiary is Intellia Securities Corp. As of September 30, 2016, the Company had not generated any revenue.
Financial Overview
For the nine months ended 30 September 2020,Intellia Therapeutics Inc revenues increased 60% to $51.4M.Net loss increased 29% to $92M. Revenues reflect anincrease in demand for the Company's products and servicesdue to favorable market conditions. Higher net lossreflects Research & Development - Balancing value increaseof 47% to $104.9M (expense), Interest income decrease of60% to $2.1M (income).
Employees: 270 as of Feb 21, 2020
Reporting Currency: U.S. Dollars
Enterprise value: $2,019M as of Sep 30, 2020
Annual revenue (TTM): $62.34M as of Sep 30, 2020
EBITDA (TTM): -$117.66M as of Sep 30, 2020
Net annual income (TTM): -$120.32M as of Sep 30, 2020
Free cash flow (TTM): -$43.50M as of Sep 30, 2020
Net Debt Last Fiscal Year: N/A
Shares outstanding: 59,080,783 as of Oct 30, 2020
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please subscribe. Our packages start at $1.00 plus tax for the first month.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.